The UK and US have concluded a significant trade agreement that will keep no duties on UK drug exports being sold in the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost funding on drugs through the National Health Service (NHS). This pledge guarantees that duties on these key exports will remain at zero for a timeframe of three years.
This development is in response to previous statements to significantly raise import taxes on patented drug products, with figures mentioned reaching 100%.
"This deal with the Britain strengthens the global environment for innovative medicines and brings much-needed equity to transatlantic medicine commerce," a statement noted.
Economic Impact
Pharmaceuticals represent one of the Britain's biggest exports to the America, which is clearly the biggest buyer for major companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of the third quarter, the UK exported pharmaceutical products valued at billions to the US. This figure made up 17.4% of total UK exports in that span.
"This guarantee protects work, increases investment and facilitates the UK to become a global hub for life sciences," a minister stated.
Specific British Pledges
The agreement involves several key commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded 20%.
Recent Tensions
This agreement comes amid a protracted dispute between the sector and the ministers over spending levels and approval rates.
The disagreement were heightened by claims that American customers were paying several times more for the same drugs than patients in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been halted or abandoned, while substantial expansions have been announced toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a proportion of its resources over the past decade.
